2025 Annual Report & Appendix 4E
Released
Released
Announcement PDF
Microba Life Sciences Limited
Appendix 4E
Preliminary final report
1. Company details
Name of entity:
ABN:
Reporting period:
Previous period:
Microba Life Sciences Limited
82 617 096 652
For the year ended 30 June 2025
For the year ended 30 June 2024
2. Results for announcement to the market
$
Revenues from ordinary activities
up
29.6% to
15,669,089
Loss from ordinary activities after tax attributable to the owners of Microba
down
Life Sciences Limited
25.1% to
(14,939,471)
Loss for the year attributable to the owners of Microba Life Sciences
Limited
25.1% to
(14,939,471)
down
Dividends
There were no dividends paid, recommended or declared during the current financial period.
Comments
The loss for the Group after providing for income tax amounted to $14,939,471 (30 June 2024: $19,938,485).
3. Net tangible assets
Reporting
period
Cents
Net tangible assets per ordinary security
Previous
period
Cents
1.57
4.21
4. Control gained over entities
Not applicable.
5. Loss of control over entities
Not applicable.
6. Dividends
Current period
There were no dividends paid, recommended or declared during the current financial period.
Previous period
There were no dividends paid, recommended or declared during the previous financial period.
7. Dividend reinvestment plans
Not applicable.
Annual Report 2025
1
Microba Life Sciences Limited
Appendix 4E
Preliminary final report
8. Details of associates and joint venture entities
Not applicable.
9. Foreign entities
Details of origin of accounting standards used in compiling the report:
Not applicable.
10. Audit qualification or review
Details of audit/review dispute or qualification (if any):
The financial statements have been audited and an unmodified opinion has been issued.
11. Attachments
Details of attachments (if any):
The Annual Report of Microba Life Sciences Limited for the year ended 30 June 2025 is attached.
12. Signed
Signed ___________________________
Date: 26 August 2025
Pasquale Rombola
Chair
Brisbane
Authorised for release by the Board.
Annual Report 2025
2
Annual Report
Financial Report for the year ended 30 June 2025
Microba Life Sciences Limited
and controlled entities
Microba Life Sciences Limited | ABN 82 617 096 652
Corporate
Directory
Directors
Pasquale Rombola
Ian Frazer
Gene Tyson
Richard Bund
Hyungtae Kim
Jacqueline Fernley
Key management
Luke Reid (Chief Executive Officer)
personnel
James Heath (Chief Financial Officer)
Company secretaries
James Heath
Peter Webse (resigned 31 August 2024)
Registered office and
Microba Life Sciences Limited
principal place of business
Level 10
324 Queen Street
Brisbane QLD
Australia
Share register
Automic Pty Ltd
Level 35
477 Collins Street
Melbourne VIC
Australia
Auditor
Pitcher Partners
Level 38
345 Queen Street
Brisbane QLD
Australia
Solicitors
Thomson Geer
Level 28
1 Eagle Street
Brisbane QLD
Australia
Stock exchange listing
Microba Life Sciences Limited shares are listed on the Australian
Securities Exchange (ASX code: MAP)
Website
www.microba.com
Corporate
The Company’s corporate governance statement is located at the
Governance Statement
Company’s website: https://ir.microba.com/
Annual Report 2025
4
Table of
Contents
Performance Highlights
06
Chair, Deputy Chair & CEO Letter
07
Operating & Financial Review
10
Financial Review
11
Diagnostics
13
Therapeutics
21
Material Business Risks
24
Directors’ Report
27
Financial Statements
43
ASX Additional Information
93
Annual Report 2025
5
Performance
Highlights
$15.7m
Strong Revenue and Cash Receipts Growth
•
30% YoY growth in revenue, reaching $15.7 million for the year whilst
discontinuing legacy products
•
36% YoY growth in cash receipts totalling $17.0 million
Record Core Test Volumes in Australia
•
MetaXplore test sales grew 136%, with 11,065 tests sold in FY25 and an
annualised run-rate of 13,800 tests by year-end.
•
MetaPanel continued to advance in early market development with over
850 tests sold in FY25
Unlocked United Kingdom acquisition
71.4%
identifying actionable results
•
MetaXplore successfully launched and expanded to full market access
at the end of Q4, delivering 429 tests for the quarter
•
MetaXplore at year-end represented ~66% of all gastrointestinal tests sold
by Microba’s UK business
Delivered landmark utility study results
•
Landmark GI Study Results from over 4,600 patients with 71.4% identifying
actionable results
•
Breakthrough Study Results in over 800 patients, with 20% of MetaPanel
tests positive for a pathogen, and 78% of results often missed by routine
pathology tests
•
Compelling results in Inflammatory Bowel Disease (IBD) patients, with
more than 35% of patients experiencing a disease flare testing positive for
a pathogen with MetaPanel. More than 60% of these pathogens would be
missed using current routine testing methods
Therapeutics positioned for partnering
$11.74m
Annual Report 2025
•
Completed pre-clinical R&D pipeline plans, including successful
completion of a world-first autoimmune therapeutics discovery program
with partner Ginkgo Bioworks, yielding six promising leads.
•
Internal R&D largely concluded, and all core IP assets preserved,
therapeutic programs transitioned from R&D focus to capital light
partnering, actively pursuing strategic partnerships
Strong cash position
•
Cash and equivalents were $11.74 million as at 30 June 2025
•
The balance sheet was strengthened with a successful capital raise of $14.5
million, of which $8.45 million was received in August 2025
•
A further $3 million is expected from the FY25 R&D Tax Incentive, expected
to be received in H1 FY26
6
01
Chair,
Deputy Chair
& CEO Letter
Annual Report 2025
7
Message from the Chair,
Deputy Chair & CEO
Dear Shareholders,
FY25 has been a year of transformative growth and strategic accomplishment for Microba. We began the
year with a clear focus: to accelerate transition of our core testing products at the forefront of this new
major $25B diagnostic category, and we are pleased that we have delivered on this objective. Microba’s core
diagnostic offerings, MetaXplore and MetaPanel, achieved record sales and clinical adoption over the past
year, growing over 160%. In Australia, we saw sustained momentum with clinician registrations, test sales
volumes and revenue each growing quarter on quarter through the year. In the United Kingdom, through
the successful integration of our Invivo Healthcare acquisition, we opened a key market, and test sales are
rapidly gathering pace after expanding to full market access at the end of the year. Across both Australia and
the UK, our strategic decision to phase out legacy products and focus on our core test portfolio is bearing
fruit - our core testing products are now driving sustained revenue growth and moving us closer to our three
year target of group breakeven.
Crucially, FY25 was about focus and execution. We streamlined our operations to concentrate on the
products that are competitively positioned to win this major new diagnostic category. This meant
completing the migration away from, and discontinuation of legacy offerings. These include the Insight
consumer test, Research Services offering, and the EcologiX test suite and doubling down on MetaXplore
and MetaPanel diagnostic products that deliver high value to clinicians and patients. The impact is evident:
Microba delivered 30% revenue growth for the year and record quarterly test sales, all whilst discontinuing
legacy products and their associated revenue. While our targeted investment in sales, marketing, and
product development still resulted in our bottom line as an overall loss for the year, these investments have
continued to lay the foundation for scalable, profitable growth in the future. We have managed our costs
carefully and ended the year with a robust cash position of $11.74 million, which was further strengthened
by a $14.5 million capital raise supported by major existing and new shareholders, with $8.45 million
successfully settled in August 2025. With this strengthened balance sheet, we are well-funded to execute
our growth strategy and reach our regional break-even objectives for FY26.
Microba’s mission to improve human health through microbiome science remains our driving force. In
FY25, we not only grew commercially but also demonstrated the real-world clinical utility of our testing
technology. The release of landmark study results showed that our tests provide actionable insights and
transformational health outcomes for a range of patient groups with chronic gastrointestinal disorders,
powerful proof-points that are supporting more healthcare practitioners to adopt our solutions every day.
We also moved to consolidate our Therapeutics investments and assets for partnering. We have completed
deep pre-clinical and early clinical de-risking of our live biotherapeutic assets. The market is waiting to
see a definitive Phase1b/2a clinical trial result in a chronic disease setting for this new live biotherapeutic
modality. Given the capital requirements, the board and executive made the strategic decision to let peers
complete that work and deploy that capital. We have suspended all R&D activities, while preserving our core
IP, position ourselves for pharmaceutical partner transactions, and will await maturing of the microbiome
therapeutics sector including modality validating trial results. This approach preserves shareholder value and
lets us focus on the immediate growth opportunity in diagnostics, whilst maintaining the value and potential
upside of our therapeutic assets.
Annual Report 2025
8
Message from the Chair,
Deputy Chair & CEO
Looking ahead to 2026 and beyond, we are focused and confident. The groundwork laid this year – in
market expansion, product validation, and operational focus – positions Microba to capitalise on the first
$25+ billion subsegment of the $125B microbiome diagnostics market opportunity. Our immediate priorities
are clear: continue driving adoption of MetaXplore and MetaPanel in our existing markets, achieve our
regional break even objectives, and maintain disciplined financial management to rapidly drive towards selfsustaining growth. We expect FY26 to build on FY25’s momentum, with each quarter surpassing the last as
we deepen our clinician network and roll out planned product enhancements.
On behalf of the Board, we would like to thank Microba’s employees and partners for their hard work and
dedication during this pivotal year. We also extend our gratitude and thanks to our shareholders for their
continued support and belief in Microba’s vision. The progress we have made in FY25 has been a true team
effort, and we are only at the beginning of unlocking Microba’s impact on patient health. We enter the new
year with focus and confidence, and we remain steadfast in our commitment to delivering value, both for
patients in need of better health solutions and our shareholders.
Yours sincerely,
Mr. Pasquale Rombola
Prof. Ian Frazer (AC)
Dr. Luke Reid
CHAIR
DEPUTY CHAIR
CHIEF EXECUTIVE OFFICER
Annual Report 2025
9
02
Operating &
Financial Review
Annual Report 2025
10
Financial
Review
The financial year ending 30 June 2025 was a transformative year for Microba Life
Sciences, marked by strong growth in core operations, a streamlined portfolio
of tests, and sharp focus across the business. Microba Group revenue grew to
$15.7 million, up 30% on FY24 ($12.1 million), with momentum building across
both the Australian and UK markets. This growth was underpinned by accelerating
adoption of MetaXplore™, increasing clinician engagement with MetaPanel™, and
a stable performance from our Invivo UK supplements business.
In Australia, MetaXplore™ continued to establish itself as the market-leading microbiome diagnostic, with
record clinician adoption supported by landmark study results involving more than 4,600 patients. Average
selling prices strengthened through the year, and June 2025 closed the financial year with a record month
for test volumes. MetaPanel™, though still in the early stages of commercialisation, gained steady traction
with clinicians through education and strong key opinion leader support.
In the United Kingdom, FY25 was highlighted by MetaXplore™ achieving full market access in Q4, unlocking
rapid growth in ordering clinicians and establishing a strong platform for FY26. The Invivo supplement
portfolio delivered annual revenue of $5.1 million, with particularly strong performance from Invivo owned
and branded supplement formulations such as PHGG. As planned, distribution of lower-margin thirdparty products was reduced, with customers successfully transitioned to higher-margin lines. Legacy
testing services under the EcologiX brand were wound down, with the majority of customers migrated to
MetaXplore™ by year end.
Gross profit increased to $7.4 million, representing a gross margin of 47.5% (FY24: 48.8%). The slight
reduction reflects targeted promotional pricing and transitional costs associated with the UK product
launch. Importantly, margins benefitted from improved product mix, operational efficiencies, and the
exit of low-margin legacy services, positioning the Company for margin expansion as volumes scale
further in FY26.
Operating expenditure was $32.23 million in FY25 (FY24: $32.82 million) a slight decrease year on year
despite the expanded operational footprint. During FY25 operating expenses were focussed on revenuefacing capability, with the largest expense category being employee expenses which increased to $16.49
million (FY24: $11.62 million), primarily reflecting the full year ownership of Invivo’s operations. Research &
Development expenditure reduced to $2.01 million (FY24: $10.84 million) following the move to stop R&D
and transition to focus on partnering . Depreciation and amortisation of $4.43 million (FY24: $2.87 million)
reflected a full year of amortisation of intangibles acquired with Invivo and ongoing capital investment in
Microba’s products and cloud infrastructure, consulting increased to $3.42 million (FY24: $2.25 million)
associated with increased platform investment and targeted advisory engagements.
The Group recorded a net loss after tax of $14.94 million, a material improvement on the FY24 net loss of
$19.94 million. This reflects both the higher revenue base, gross profit, reduction in R&D and the benefits
of continued cost discipline. Microba is on a positive path towards its stated target of achieving of regional
break-even in Australia and the UK during FY26.
Annual Report 2025
11
Financial
Review
Cash at bank was $11.74 million at 30 June 2025, supported by completion of Tranche 1 of the $14.5 million
capital raise pre 30 June 2025. A further $8.5 million (Tranche 2 and SPP) was received in August 2025,
strengthening the balance sheet. Operating cash outflows improved to $12.0 million (FY24: $15.6 million).
The Company also benefitted from the Australian Government’s R&D Tax Incentive, receiving $6.0 million in
early FY25, with a further $3 million expected in H1 FY26.
Microba enters FY26 with strong sales momentum, a focused portfolio centred on high-margin diagnostics
and supplements, and a solid financial foundation for growth. The combination of market leading products,
growing clinician adoption, expanding international reach, and disciplined cost management, positions the
Company to build on its leadership in microbiome diagnostics and deliver long-term shareholder value.
Annual Report 2025
12
Review of Operations & Activities
DIAGNOSTICS
GROWTH - Personal Testing
Core tests & clinical software winning a major new $25B diagnostic category.
Together, MetaXplore and MetaPanel form the core of Microba’s Growth product
segment and are the primary engines driving the Company’s revenue expansion.
MetaXplore
Microba’s flagship MetaXplore gastrointestinal disorders test saw strong adoption by innovator and early
adopter clinicians spanning integrative medicine, general practice and gastroenterology specialists.
Continued Growth in Test Volumes
4,500
+88%
4,000
3,500
3,000
2,500
2,000
1,500
1,000
500
-
Q4FY24
MetaXplore (AU)
Q1FY25
Q2FY25
MetaPanel (AUS)
Q3FY25
Q4FY25
MetaXplore (UK)
Real-world evidence was released during the year to support MetaXplore’s clinical value: results from a
large-scale study (over 4,600 Australian patients) demonstrated that MetaXplore™ can support clinicians
to identify and address underlying gut issues that often go undetected by conventional testing. In 71.4%
of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers
Annual Report 2025
13
Review of Operations & Activities
DIAGNOSTICS
of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of
MetaXplore™ patients in a separate study of follow up survey results reported improvement of symptoms
after their care was guided by the test results.
These results highlight the clinical value of MetaXplore™ test results in advancing outcomes for patients with
chronic lower gastrointestinal disorders, highlighting the potential to reshape clinical management of these
conditions and set a new standard of care.
41.9%
71.4%
Positive
Multiple
markers
Microbiome
marker
19.6%
9.9%
28.7%
Negative
Gastrointestinal
marker
Microba’s investment in
targeted sales, and educational outreach, including hosting clinical webinars and
Product-Accelerated
Growth
conferences, has continued to drive practitioner engagement and adoption. This is combined with continued
Moving
through the adoption curve powered by features that
advancement in the product aligned to the product roadmap leading the clinical utility, interpretability,
address
higher levels of market demands over time
actionability and integration of this testing into clinical and business workflows for healthcare professionals.
Enhanced Interpretability
Enhanced Actionability
Enhanced Business Integration
Enhanced Workflow Integration
E.g. Health Categories, Marker Cards
E.g. Key findings, Suggested Actions
E.g. Paid by Clinic, PMS integration
E.g. Report Sharing, Refer to Specialist
Combine multiple markers into smart,
clear, synthesized, clinical findings in the
context of the patient.
Advanced scientific and medical logic with
beautiful design that prioritise treatment
actions and enable clinicians to design a
personalized care plan.
Clinic features that enable more seamless
integration with their business models (E.g.
including our test in their care packages).
Patient treatment requires a multi-disciplinary
care team enabled by multiple collaboration
features including rapid referrals to trained
specialists.
Annual Report 2025
14
13
Review of Operations & Activities
DIAGNOSTICS
Australia results:
During the year we saw over 1,250 clinicians refer and generate over 11,065 test sales continuing a trend of
consistent strong half on half growth. This growth was underpinned by both an increase in the number of
ordering clinicians and higher repeat orders per clinician as confidence in the test’s utility continues to grow.
MetaXplore Test Sales Volume (AU)
MetaXplore All Time Ordering Clinicians (AU)
6673
1488
4392
1036
2907
721
1782
955
H2 FY23 H1 FY24 H2 FY24 H1 FY25 H2 FY25
539
185
H2 FY23 H1 FY24 H2 FY24 H1 FY25 H2 FY25
United Kingdom results:
Microba’s UK team made significant strides in transitioning the business from its legacy offerings to
Microba’s cutting-edge testing. In October 2024, a select group of Invivo’s existing clinician customer base
was introduced to Microba’s technology under a closed group early access program, and by May 2025 the
Company achieved full market access for the MetaXplore test (all regulatory, logistical, operational and goto-market requirements in place to sell MetaXplore across the UK). The impact was immediate: MetaXplore
sales in the UK accelerated sharply with June delivering record sales as new clinicians onboarded and
commenced referring the test. In Q4 alone, 429 MetaXplore tests were sold in the UK, up 74% quarteron-quarter. By the end of June, MetaXplore comprised approximately two-thirds of all gastrointestinal test
sales in the UK business, strong uptake in a short time period, highlighting successful migration of former
EcologiX (legacy test) users to the MetaXplore product in conjunction with adoption from new customers.
Annual Report 2025
15
Review of Operations & Activities
DIAGNOSTICS
MetaXplore Test Sales
500
450
400
350
300
250
200
150
100
50
-
Q3FY25
Q2FY25
Q4FY25
MetaPanel
Microba’s advanced world-first NATA accredited test for diagnosing gastrointestinal pathogens made progress
across the year in early market development. Distributed nationally in partnership with Sonic Healthcare, combined
investments in targeted sales, KOL development, and educational outreach (including hosting clinical webinars
and conferences), has continued to drive practitioner engagement and adoption in this market development
phase for this test. This resulted in over 502 clinicians referring and generating over 850 test sales for the year.
MetaPanel Test Sales Volume (AU)
MetaPanel Ordering Clinicians (AU)
467
127
112
402
155
39
0
H1 FY24
Annual Report 2025
H2 FY24
H1 FY25
H2 FY25
H2 FY24
H1 FY25
H2 FY25
16
Review of Operations & Activities
DIAGNOSTICS
Significant study results were released with a cohort of ~800 patients with suspected gastrointestinal
infections, 20% returned positive pathogen results – of which 78% were findings that traditional routine
pathology had missed. Further a cohort of patients with inflammatory bowel disease showed that >35% of IBD
patients experiencing a disease flare were positive for a gastrointestinal (GI) pathogen, and more than 60%
of these pathogens would be missed using current routine testing methods. These results, combined with
influential partnerships (e.g. The Colonoscopy Clinic, a major GI practice) to integrate MetaPanel testing into
their standard clinical protocols, are helping establish MetaPanel as an advanced but routine diagnostic tool.
Released to ASX 30 April 2025
Released to ASX 14 May 2025
Released to ASX 21 May 2025
Inflammatory Bowel Disease (IBD)
Chronic GI Symptoms
GI Infectious Disease
• MetaPanel™ test identifies
gastrointestinal pathogens
in >35% of IBD patients
experiencing flare
• 71.4% of reports from 4,616 patients
identified actionable results
• Analysis of 889 MetaPanel™ tests
shows that:
• A separate study of 84 patients
by Microba who received
MetaXplore-guided care found
that 65.5% reported health
improvements after following
their clinician’s recommendations
• 20.0% of patients test positive
for a pathogen that can cause
gastrointestinal infection
• >60% of these pathogens are
missed by current routine testing
methods
• These findings have the potential
to shift treatment protocols and
provide a new path to remission
for IBD patients, avoiding
unnecessary therapy escalation
or surgery
“These results are compelling, both as
a clinical use case for MetaPanel, and
for the future of precision medicine in
gastroenterology. For clinicians like myself
managing complex IBD cases, the ability to
detect pathogens missed by routine testing
could transform how patients are treated.”
Associate Professor Graham Radford-Smith
Annual Report 2025
• These results highlight the
clinical value of MetaXplore test
results in advancing outcomes
for patients with chronic lower
gastrointestinal disorders,
highlighting the potential to
reshape clinical management of
these conditions and set a new
standard of care
• 78.4% of the pathogens
detected by MetaPanel are
often missed by routine
pathology tests
• Additionally, 58.3% of tests reveal
abnormal microbiome results
• 100% of patients treated
for a pathogen detected
by MetaPanel experienced
complete symptom resolution
in an independent study.
“MetaXplore enables me to objectively identify
microbiome dysbiosis, evaluate dietary quality,
and direct patients toward evidence-based
nutritional strategies. Importantly, it helps
differentiate patients with normal GI and
microbial profiles who may benefit from
psychological support rather than further
invasive testing or pharmacological escalation.”
17
Review of Operations & Activities
DIAGNOSTICS
BASE – Supplements & International Partnerships
To continue with opportunity for future growth.
These opportunities are being maintained and positioned to support future growth
opportunities via regional expansion of Serviceable Obtainable Market (SOM), and
expansion of customer Lifetime Value (LTV)
Supplements
A core component of the Invivo Healthcare acquisition in December 2023, was their nutritional supplements
business. Within that business there are two components:
1) A distribution right to sell a brand called Designs for Health, which is a respected US brand, into the UK.
Which Invivo have been distributing for many years; and
2) A compelling, but relatively new portfolio of well formulated, evidence based Invivo owned and branded
supplements; and
Over the course of this year, with intense focus on growth of Microba’s core testing products, supplement
sales and revenues were maintained. At the end of the year, a strategic focus was applied to Invivo’s own
branded formulations, which largely carry higher margins. As a result, while total supplement revenue in the
UK saw a minor decline in Q4 (sales were $1.1 million, down ~11% vs PCP), sales of Invivo’s flagship products
grew (the top-selling PHGG prebiotic recorded multiple record sales months in Q4 – up 12% vs PCP). This
strategy showed what is possible with the supplements business, and we expect to gradually improve
revenue and margins in FY26, and set a foundation for future growth for the supplements business.
Annual Report 2025
18
Review of Operations & Activities
DIAGNOSTICS
Supplement Unit Sales (UK)
80,000
Supplement Revenue (UK)
$3,000,000
70,000
$2,500,000
60,000
$2,000,000
50,000
40,000
$1,500,000
30,000
$1,000,000
20,000
$500,000
10,000
0
0
H2 FY24
H1 FY25
H2 FY25
H2 FY24
H1 FY25
H2 FY25
International Partnerships
Outside of Australia and the UK where we are focused and partnered with Sonic Healthcare, Microba has
strategically maintained its distribution partnerships with SYNLAB (EU and LATAM), and Genova (US). While
relatively minor in revenue, these strategic relationships continue to be actively maintained with legacy
products aligned to our future European and United States geographical expansion strategy.
Annual Report 2025
19
Review of Operations & Activities
DIAGNOSTICS
LEGACY - Personal Testing
Products & services being discontinued & phased out.
These products and services supported initial revenue generation, and
development of our world leading microbiome databank
Aligned to the strategic focus on our core testing products, we have made great progress in discontinuing
all legacy products and services.
Insight: Non-diagnostic
Research Services: Delivering
EcologiX range: Basic
consumer microbiome test.
professional contract research
microbiome tests spanning GI,
Enabled Microba to stand up
services to corporates and
Vaginal, Oral & Urinary testing
a metagenomic microbiome
research institutes using
and a small assortment of tests
test, develop its world leading
Microba’s leading technology
from other providers distributed
microbiome databank, and
and capability. In October 2024,
through Invivo. Acquired in UK
ultimately develop Microba’s
Microba announced the strategic
Invivo acquisition in Dec 2023
world leading diagnostic
divestment of its research
with the strategy to replace
products. Insight revenues in
services operations to Clinical
with Microba’s world leading
Australia ended Dec 2024, and
Microbiomics (CMC), a specialized
diagnostic tests. The migration
customers where appropriate
research provider. Aligned to
of customers from the legacy
migrated to MetaXplore.
this divestment, H2 FY25 saw
EcologiX products to MetaXplore
International partner Insight
the winding down of Microba’s
is on track with MetaXplore now
revenues to continue.
research services operations,
representing a majority of all GI
marking the end of the “Research
tests sold in the UK. Customers
Testing” revenue segment as a
were notified of EcologiX range
reportable unit going forward.
discontinuation in May-25,
This was an orderly transition that
sales formally close in at the
has allowed Microba to reallocate
end of July-25, and EcologiX
capital and personnel to our core
test processing will close in
diagnostic testing business, while
October-25.
still upholding commitments
to research service customers
through a strategic acquirer.
Annual Report 2025
20
Review of Operations & Activities
THERAPEUTICS
R&D Highlights
Live Biotherapeutics
•
Early in the year, Microba successfully concluded a world-first drug discovery program in autoimmune
disease in partnership with Ginkgo Bioworks. This multi-year collaboration screened thousands of gut
bacterial strains for therapeutic properties, yielding six lead strains with compelling disease-relevant
activity against autoimmune targets. These novel leads have been added to Microba’s IP portfolio,
expanding our pipeline of therapeutic candidates.
•
In parallel, Microba’s in-house R&D team made progress in the immuno-oncology program, where it
is exploring bacteria with immune-modulatory anti-cancer properties. In FY25, encouraging data from
animal models and immune assays demonstrated anti-tumour activity for certain lead bacteria.
Next Generation Probiotics
•
In FY25 Microba continued its collaboration with global probiotics leader, International Flavors &
Fragrances (IFF), building on the initial agreement in gut health, a second agreement with IFF was
signed to develop new microbiome-based treatments for allergies.
Share your feedback
Discover